Intouch Solutions

FEBRUARY 1, 2022

Ford discussed his vision and the promise of healthcare technology: to bring care that’s more personal and precise, proactively manage health, detect disease early, and even prevent it from happening in the first place. Why This Matters for Pharma It’s critical to evaluate patient and HCP experiences in the context of a virtual care setting.

Branding 98

Branding Marketing Big Data Clinical Trials 98

pharmaphorum

JUNE 18, 2021

In facts, caregivers often take on the task of searching for the best pathways for those they care for; also, they have to learn to provide care to their assisted ones, which is no simple undertaking. In a patient intelligence research project conducted by PIPHealth in 2020, the importance of the carer’s voice came to light.

Research 76

Research Development Production Marketing 76

pharmaphorum

JANUARY 28, 2021

It has been five years since the first biosimilar launched in United States market—marking the first steps in expanding access to innovative biologic-based treatments that help patients manage and treat difficult illnesses such as cancer, rheumatoid arthritis, and other life-altering diseases. million patients. million patients.

Marketing 119

Marketing Insulin HR Production 119

pharmaphorum

JANUARY 27, 2023

Having previously spoken with Dr Mullen three years ago when she was country medical director for the UK & Ireland at GSK – on the topic of patient centricity and embedding that focus within the core of a pharmaceutical company – our recent interview provided some interesting insights into the changing landscape of the industry.

Clinical Trials 111

Clinical Trials Clinical Trials Trials Development 111

Pfizer

JANUARY 27, 2023

This opinion from the CHMP confirms that the benefits of PAXLOVID in helping to reduce severe COVID-19-related outcomes, including hospitalization and death, in high risk patients continue to outweigh its potential risks. The European Commission (EC) will review the CHMP recommendation and is soon expected to make a final decision.

Marketing 75

Marketing Production Drugs Licensing 75

Pfizer

DECEMBER 13, 2022

PAXLOVID plays an important role in helping to combat COVID-19-related hospitalizations and death in high-risk patients. Food and Drug Administration (FDA) for approval of PAXLOVID for patients who are at high risk of progression to severe disease from COVID-19. (NYSE: PFE) has reached an agreement with the U.S. Government.

Drugs 110

Drugs Licensing Licensing Production 110

Pfizer

DECEMBER 20, 2022

patients under Emergency Use Authorization as a critical tool in the fight against COVID-19. PAXLOVID is authorized for emergency use by the FDA for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) who are at high-risk for progression to severe COVID-19.

Drugs 69

Drugs Licensing Licensing Containment 69